Discover the incredible success and growth of Northwestern Health's Bluhm Cardiovascular Institute, ranked among the top 10 cardiology programs in the nation ...

Women are often underdiagnosed and undertreated when it comes to heart disease, particularly conditions like aortic stenosis.

Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an ...

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Bleakley Financial Group LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.3% during the 4th ...

Edwards maintained its 2025 financial guidance, targeting total company sales of $5.6 billion to $6 billion, with TAVR sales of $4.1 billion to $4.4 billion, TMTT sales of $500 million to $530 million ...

Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, ...

Edwards Lifesciences stock surged late Tuesday — and could retake its 50-day and 200-day lines — after beating fourth-quarter ...